Skip to main content
Erschienen in: Tumor Biology 1/2014

01.01.2014 | Research Article

Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial–mesenchymal transition biomarkers

verfasst von: Cheng-Jeng Tai, Chao-Wen Cheng, Hou-Yu Su, Wei-Yu Chen, Chun-Te Wu, Feng-Yen Lin, Chien-Kai Wang, Chen-Jei Tai, Po-Li Wei

Erschienen in: Tumor Biology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Thrombomodulin (TM) has been shown to regulate many physiological and pathological processes, including inflammation, thrombosis, and tumor progression. TM is also a natural anticoagulant that maintains circulatory homeostasis in endothelial cells. However, little is known regarding the role of TM in the progression and metastasis of cervical cancer. TM-specific RNA interference and a cDNA expression vector were used to manipulate TM expression in cervical cancer cells. Cell growth and cell migration were evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, transwell migration assays, and a biosensor system. TM silencing did not affect the growth rate of the cells. However, cell migration was dramatically enhanced after silencing of TM in HeLa cells. The overexpression of TM in cervical cancer cells only slightly influenced their proliferative capacity. After overexpression of TM in HeLa cells, their migratory capability was suppressed. Furthermore, we found that the decreased expression of E-cadherin and increase of zeb-1 and snail expression in TM-silenced cells which may be correlated with the results of knocking-down TM increases the migratory ability in this study. Our results demonstrate that TM may slightly regulate the growth but played the important role in the migratory ability of cervical cancer cells, suggesting that TM could potentially serve as a novel prognostic and therapeutic target in cervical cancer.
Literatur
1.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;27:2893–917 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;27:2893–917
2.
Zurück zum Zitat Tavassoli FA, Devilee P. World Health Organization., International Agency for Research on Cancer: Pathology and genetics of tumours of the breast and female genital organs. Lyon, IARC, 2003. Tavassoli FA, Devilee P. World Health Organization., International Agency for Research on Cancer: Pathology and genetics of tumours of the breast and female genital organs. Lyon, IARC, 2003.
3.
Zurück zum Zitat Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749–57.PubMedCrossRef Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749–57.PubMedCrossRef
4.
Zurück zum Zitat Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535–40.PubMedCrossRef Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535–40.PubMedCrossRef
5.
Zurück zum Zitat Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.PubMedCrossRef Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.PubMedCrossRef
6.
Zurück zum Zitat Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys. 2011;79:325–34.PubMedCrossRef Noordhuis MG, Eijsink JJ, Roossink F, de Graeff P, Pras E, Schuuring E, et al. Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review. Int J Radiat Oncol Biol Phys. 2011;79:325–34.PubMedCrossRef
7.
Zurück zum Zitat del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol. 2008;110:S72–76.PubMedCrossRef del Campo JM, Prat A, Gil-Moreno A, Perez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol. 2008;110:S72–76.PubMedCrossRef
8.
Zurück zum Zitat Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–81.PubMedCrossRef Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial–mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–81.PubMedCrossRef
9.
Zurück zum Zitat Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.PubMedCrossRef Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.PubMedCrossRef
10.
Zurück zum Zitat Murakami A, Nakagawa T, Fukushima C, Torii M, Sueoka K, Nawata S, et al. Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. Oncol Rep. 2008;19:99–104.PubMed Murakami A, Nakagawa T, Fukushima C, Torii M, Sueoka K, Nawata S, et al. Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. Oncol Rep. 2008;19:99–104.PubMed
11.
Zurück zum Zitat Esmon CT. The roles of protein c and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743–6.PubMed Esmon CT. The roles of protein c and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743–6.PubMed
12.
Zurück zum Zitat Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M. Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays. Dev Biol. 1990;140:113–22.PubMedCrossRef Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M. Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays. Dev Biol. 1990;140:113–22.PubMedCrossRef
13.
Zurück zum Zitat Hanly AM, Winter DC. The role of thrombomodulin in malignancy. Semin Thromb Hemost. 2007;33:673–9.PubMedCrossRef Hanly AM, Winter DC. The role of thrombomodulin in malignancy. Semin Thromb Hemost. 2007;33:673–9.PubMedCrossRef
14.
Zurück zum Zitat Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood. 2008;112:3661–70.PubMedCrossRef Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood. 2008;112:3661–70.PubMedCrossRef
15.
Zurück zum Zitat Tezuka Y, Yonezawa S, Maruyama I, Matsushita Y, Shimizu T, Obama H, et al. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res. 1995;55:4196–200.PubMed Tezuka Y, Yonezawa S, Maruyama I, Matsushita Y, Shimizu T, Obama H, et al. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res. 1995;55:4196–200.PubMed
16.
Zurück zum Zitat Kim SJ, Shiba E, Ishii H, Inoue T, Taguchi T, Tanji Y, et al. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study. Anticancer Res. 1997;17:2319–23.PubMed Kim SJ, Shiba E, Ishii H, Inoue T, Taguchi T, Tanji Y, et al. Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study. Anticancer Res. 1997;17:2319–23.PubMed
17.
Zurück zum Zitat Liu PL, Tsai JR, Chiu CC, Hwang JJ, Chou SH, Wang CK, et al. Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer. Mol Carcinog. 2010;49:874–81.PubMedCrossRef Liu PL, Tsai JR, Chiu CC, Hwang JJ, Chou SH, Wang CK, et al. Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer. Mol Carcinog. 2010;49:874–81.PubMedCrossRef
18.
Zurück zum Zitat Hanly AM, Redmond M, Winter DC, Brophy S, Deasy JM, Bouchier-Hayes DJ, et al. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer. 2006;94:1320–5.PubMedCentralPubMedCrossRef Hanly AM, Redmond M, Winter DC, Brophy S, Deasy JM, Bouchier-Hayes DJ, et al. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer. 2006;94:1320–5.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology. 1995;21:1285–90.PubMedCrossRef Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology. 1995;21:1285–90.PubMedCrossRef
20.
Zurück zum Zitat Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, et al. Knockdown of thrombomodulin enhances HCC cell migration through increase of zeb1 and decrease of E-cadherin gene expression. Ann Surg Oncol. 2010;17:3379–85.PubMedCrossRef Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, et al. Knockdown of thrombomodulin enhances HCC cell migration through increase of zeb1 and decrease of E-cadherin gene expression. Ann Surg Oncol. 2010;17:3379–85.PubMedCrossRef
21.
Zurück zum Zitat Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-sign. Proc Natl Acad Sci U S A. 2008;105:3690–5.PubMedCentralPubMedCrossRef Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-sign. Proc Natl Acad Sci U S A. 2008;105:3690–5.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol. 2008;10:211–9.PubMedCrossRef Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol. 2008;10:211–9.PubMedCrossRef
23.
Zurück zum Zitat Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–12.PubMedCrossRef Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–12.PubMedCrossRef
24.
Zurück zum Zitat Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703–9.PubMedCrossRef Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703–9.PubMedCrossRef
25.
Zurück zum Zitat Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone GRP78/BIP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008;68:498–505.PubMedCrossRef Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone GRP78/BIP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008;68:498–505.PubMedCrossRef
26.
Zurück zum Zitat Wei PL, Kuo LJ, Huang MT, Ting WC, Ho YS, Wang W, An J, Chang YJ. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann Surg Oncol. 2011;18:1782–90 Wei PL, Kuo LJ, Huang MT, Ting WC, Ho YS, Wang W, An J, Chang YJ. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann Surg Oncol. 2011;18:1782–90
27.
Zurück zum Zitat Lien YC, Wang W, Kuo LJ, Liu JJ, Wei PL, Ho YS, Ting WC, Wu CH, Chang YJ. Nicotine promotes cell migration through alpha7 nicotinic acetylcholine receptor in gastric cancer cells. Ann Surg Oncol. 2011;18:2671–9 Lien YC, Wang W, Kuo LJ, Liu JJ, Wei PL, Ho YS, Ting WC, Wu CH, Chang YJ. Nicotine promotes cell migration through alpha7 nicotinic acetylcholine receptor in gastric cancer cells. Ann Surg Oncol. 2011;18:2671–9
28.
Zurück zum Zitat Wang L, Wang Q, Li HL, Han LY. Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma—relationship with prognosis. Asian Pac J Cancer Prev. 2013;14:2113–8.PubMedCrossRef Wang L, Wang Q, Li HL, Han LY. Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma—relationship with prognosis. Asian Pac J Cancer Prev. 2013;14:2113–8.PubMedCrossRef
29.
Zurück zum Zitat Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333–59.PubMedCrossRef Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333–59.PubMedCrossRef
30.
Zurück zum Zitat Bast Jr RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22 Suppl 8:viii5–viii15.PubMedCrossRef Bast Jr RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22 Suppl 8:viii5–viii15.PubMedCrossRef
31.
Zurück zum Zitat Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S116–130.PubMedCrossRef Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer. 2011;47 Suppl 3:S116–130.PubMedCrossRef
32.
Zurück zum Zitat Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRef Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.PubMedCrossRef
33.
Zurück zum Zitat Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72:1878–89.PubMedCentralPubMedCrossRef Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 2012;72:1878–89.PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31:4619–29 Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, Dai Y. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31:4619–29
35.
Zurück zum Zitat Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol. 1997;28:922–8.PubMedCrossRef Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol. 1997;28:922–8.PubMedCrossRef
36.
Zurück zum Zitat Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer. 1994;58:393–9.PubMedCrossRef Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer. 1994;58:393–9.PubMedCrossRef
37.
Zurück zum Zitat Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, et al. Emt transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12:91.PubMedCentralPubMedCrossRef Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, et al. Emt transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12:91.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Hsu YM, Chen YF, Chou CY, Tang MJ, Chen JH, Wilkins RJ, et al. Kcl cotransporter-3 down-regulates E-cadherin/beta-catenin complex to promote epithelial–mesenchymal transition. Cancer Res. 2007;67:11064–73.PubMedCrossRef Hsu YM, Chen YF, Chou CY, Tang MJ, Chen JH, Wilkins RJ, et al. Kcl cotransporter-3 down-regulates E-cadherin/beta-catenin complex to promote epithelial–mesenchymal transition. Cancer Res. 2007;67:11064–73.PubMedCrossRef
39.
Zurück zum Zitat Cheng Y, Zhou Y, Jiang W, Yang X, Zhu J, Feng D, et al. Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma. Hum Pathol. 2012;43:1213–20.PubMedCrossRef Cheng Y, Zhou Y, Jiang W, Yang X, Zhu J, Feng D, et al. Significance of E-cadherin, beta-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma. Hum Pathol. 2012;43:1213–20.PubMedCrossRef
40.
Zurück zum Zitat Myong NH. Loss of E-cadherin and acquisition of vimentin in epithelial–mesenchymal transition are noble indicators of uterine cervix cancer progression. Korean journal of pathology. 2012;46:341–8.PubMedCentralPubMedCrossRef Myong NH. Loss of E-cadherin and acquisition of vimentin in epithelial–mesenchymal transition are noble indicators of uterine cervix cancer progression. Korean journal of pathology. 2012;46:341–8.PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008;21:912–23.PubMedCrossRef Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008;21:912–23.PubMedCrossRef
42.
Zurück zum Zitat Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, et al. The transcription factor zeb1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006;66:3893–902.PubMedCrossRef Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, et al. The transcription factor zeb1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006;66:3893–902.PubMedCrossRef
43.
Zurück zum Zitat Kao YC, Wu LW, Shi CS, Chu CH, Huang CW, Kuo CP, et al. Downregulation of thrombomodulin, a novel target of snail, induces tumorigenesis through epithelial–mesenchymal transition. Mol Cell Biol. 2010;30:4767–85.PubMedCentralPubMedCrossRef Kao YC, Wu LW, Shi CS, Chu CH, Huang CW, Kuo CP, et al. Downregulation of thrombomodulin, a novel target of snail, induces tumorigenesis through epithelial–mesenchymal transition. Mol Cell Biol. 2010;30:4767–85.PubMedCentralPubMedCrossRef
Metadaten
Titel
Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial–mesenchymal transition biomarkers
verfasst von
Cheng-Jeng Tai
Chao-Wen Cheng
Hou-Yu Su
Wei-Yu Chen
Chun-Te Wu
Feng-Yen Lin
Chien-Kai Wang
Chen-Jei Tai
Po-Li Wei
Publikationsdatum
01.01.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1005-7

Weitere Artikel der Ausgabe 1/2014

Tumor Biology 1/2014 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.